Focus on cutting-edge scientific and technological innovation and upgrading of traditional industries

　　The Industrial 4.0 Revolution sweeping the world has affected almost every industry, including the supply chain management of all industries.

　　In the past, supply chain management was a headache for all industries, because the traditional supply chain involved a lot of fuzzy and inaccessible data, which swallowed up cost, time and patience like a "black hole". Industry 4.0 will give birth to a new digital supply chain and realize more complex and streamlined supply chain management.

　　Digital supply chain is an important direction of industrial solutions and business processes in the future, including not only logistics, warehousing, transportation, but also engineering, research and development, manufacturing and asset management.

　　With the application of many innovative technologies such as artificial intelligence, Internet of Things and blockchain in the supply chain, the traditional supply chain management is rapidly moving towards digitalization, intelligence and controllability.

　　1. Cross-platform asset tracking that connects everything

　　At present, GPS positioning is a mature technology with low price and low management cost, which is widely used in various fields. Through sensors connected to various assets or vehicles, the location and general time planning of assets can be obtained.

　　Enterprises can track assets through bar codes and tracking numbers, and know where products and goods are being shipped. However, this kind of tracking and monitoring is far from accurate, and it will still bring many problems and inconveniences.

　　For example, after shopping on the e-commerce platform, the logistics information shows that "the courier is delivering the goods", but we can’t know whether the courier will deliver it within the next hour or within three hours.

　　In the industrial field, this inaccurate or delayed logistics distribution will bring some confusion to the production of enterprises, and even cause the production line to stop. Especially for manufacturers who pursue zero inventory, zero inventory not only refers to the timely delivery of final products, but also includes the inventory management of raw materials and equipment needed for production.

　　Therefore, more accurate asset tracking technology will be an important direction of digital supply chain in the future. Hans Thalbauer, senior vice president of SAP, said, "We should not only create connections for goods, but also create connections for business partners. We need to connect not only suppliers, but also suppliers of suppliers. "

　　The future digital supply chain should not only connect all links in the supply chain, but also connect all factors that affect logistics distribution, such as weather, natural disasters, road infrastructure, regional economy and even political influence, so as to minimize risks.

　　For example, last year’s hurricane, which caused great damage to the American economy, affected the distribution of some suppliers’ goods, causing some automakers to shut down production. If we can get the news from the supply chain that "my supplier’s factory in Japan is affected by the earthquake and will stop production in the next two weeks", manufacturers can purchase products from suppliers in other parts of the world in time.

　　2. Timely production and forecast monitoring

　　As early as several decades ago, Toyota Motor Corporation initiated the concept of just in time to alleviate the problem of lack of cash, land and large inventory. Through the accurate management system, the response time of suppliers is shortened and the investment in process inventory is reduced.

　　But the basis of timely production is that all parts and raw materials must arrive on time. On the automobile assembly line, the shortage of any part will affect the normal production of the production line. If the distribution of parts is delayed, it may lead to product quality problems or even downtime; If the delivery is too early, the factory is not ready to receive it, which will increase the cost of inventory management.

　　In order to meet the production needs of large manufacturers, OEM will have strict delivery response time to ensure that parts can arrive at suppliers on time. However, this will bring great production pressure to suppliers. On the one hand, suppliers have to invest a lot of money in expedited transportation, and at the same time, in order to avoid the penalty of downtime caused by delayed transportation, suppliers must also maintain a certain amount of spare parts inventory.

　　Therefore, timely production can improve the production efficiency of OEM manufacturers, but it will lead to low efficiency of suppliers, thus increasing the cost of parts.

　　This requires the future digital supply chain to have the machine learning ability of real-time prediction. Through digital connection, it can realize predictive quality management, predictive manufacturing and predictive maintenance, improve the efficiency of production and distribution, and reduce costs.

　　3. Blockchain and traceability

　　The advantages of security, trust, traceability and controllability make blockchain one of the most potential new technologies. By creating a safe and transparent ledger system, all relevant stakeholders in the supply chain, such as manufacturers, retailers, logistics service providers and regulatory agencies, are brought into the same management platform, making the whole management process credible and transparent.

　　In recent years, many start-ups that use blockchain technology to reshape supply chain management have been born. At the same time, traditional logistics giants have also begun to explore the application path of blockchain.

　　For example, the shipping giant Maersk cooperated with IBM to develop the TradeLens blockchain platform, aiming at improving logistics efficiency and simplifying the documentation of global container transportation. After testing, the handling capacity of shipping documents is reduced by 10 times, and the transportation time is reduced by 40% on average. At present, nearly 100 partners around the world have joined the platform.

　　Through opening up, blockchain technology can effectively prevent price fraud, transportation delay and payment delay, eliminate middlemen and effectively reduce transaction costs.

　　In the industrial field, although the blockchain is still in the experimental and exploratory stage, once it is deeply integrated with industrial production, it will play an important role in future industrial production and digital supply chain.

　　In the future, all kinds of new technologies will allow us to look at every link of the whole supply chain more rationally from the digital point of view, and help us to continuously improve our production, analysis, maintenance and forecasting capabilities.

　　As Hans Thalbauer, Senior Vice President of Supply Chain and Internet of Things of SAP Company said, "This is a digital mirror. It is the digital twin of products, the twin of assets and a mirror of the world. This allows us to start the dynamic adjustment process. We hope to create a digital mirror image of the real world in this environment. "

This article first appeared on WeChat WeChat official account: Capital Lab. The content of the article belongs to the author’s personal opinion and does not represent Hexun.com’s position. Investors should operate accordingly, at their own risk.

　　Xinhua News Agency, Washington, June 13 th, financial observation: Trade policy is "fiercer than tiger" and American enterprises are miserable and embarrassed

　　Xinhua News Agency reporter Xu Yuan

　　The destructive trade policy of the American government is becoming the biggest threat to the development of American enterprises. In recent days, from enterprises to trade associations, from large companies to small and medium-sized enterprises, business people have criticized the US government’s protectionist measures.

　　On behalf of 661 American enterprises and trade associations, the American lobbying organization "Tariffs Hurt the Hinterland of the United States" sent a letter to US President Trump on 13th, urging the US government not to impose tariffs on goods imported from China, and to return to the negotiating table to reach a solution with China.

　　The open letter warns that American enterprises and trade associations are worried about the situation of tariff escalation. The increase in tariffs and the uncertainty surrounding Sino-US trade negotiations have caused market turmoil and posed a threat to the US economy.

　　According to the survey released by the Business Roundtable composed of executives of large American enterprises on the 12th, the "Economic Outlook Index" fell by 5.7 points to 89.5 points in the second quarter. This index reflects the sales expectations, capital expenditures and recruitment plans of American business executives for the next six months, and shows that American business circles are increasingly uneasy about the direction of US trade policy.

　　"(The US government’s trade policy) is increasing the risk of bad economic results," said Jamie Dimon, CEO of JPMorgan Chase and chairman of the Business Roundtable at the press conference that day. "The uncertainty of trade policy, the weak global economic growth and the inaction of the US government on other urgent public policy issues are worrying."

　　Tom Linebarger, chairman and CEO of Cummins, an American engine manufacturer, said that "trade (policy) is the most terrible threat to enterprise growth". He said that imposing tariffs on China’s goods exported to the United States would increase consumers’ costs and reduce the competitiveness of American enterprises.

　　American financial data software company predicts that due to the uncertain tariff policy and global economic prospects, for those multinational companies whose sales are more than half from outside the United States, their profits in the second quarter may drop by 9.3%. The company expects that Apple’s profit may drop by 14.6% in the second quarter, and Boeing’s profit may drop by as much as 43.7%.

　　The U.S. government previously announced that the tariff rate on the $200 billion list goods imported from China will be increased from 10% to 25% from May 10, 2019. The U.S. government also threatened to impose a 25% tariff on the remaining about $300 billion of goods exported from China to the United States, involving many end consumer goods.

　　Lorraine Hutchinson, an analyst at Bank of America Merrill Lynch, predicts that tariff escalation will lead to growth risks for American retail enterprises such as clothing. According to the semi-annual survey recently released by institute for supply management, about 59% of American enterprises indicated that increasing tariffs would lead to higher product prices. Wal-Mart, an American retail giant, also said that tariffs will force it to raise the retail price of goods.

　　Tariffs not only hit large enterprises, but also make life more difficult for small enterprises. USA Today reported a few days ago that the negative impact of tariffs has exhausted the energy of many small American enterprises because their cost digestion ability is worse than that of large enterprises. Adjusting the supply chain will cost hundreds of thousands or even millions of dollars, which is unbearable for many small enterprises.

　　[Global Network Reporter Li Dongyu] "Although I don’t drink, I always prefer American wine to French wine." On July 26, local time, when Trump once again issued a tariff threat to French-made wines, he used this sentence to express his support for domestic wines.

　　As a response to France’s recent announcement to levy a digital service tax on global technology giants, according to The New York Times, Trump first said on Twitter on the 26th, "France has just imposed a digital tax on our great American technology companies. If someone wants to tax them, it should also be their motherland — — America. "

　　Then, he added, "We will soon announce substantive reciprocal action against Macron’s foolish behavior."

　　Interestingly, Trump did not explicitly say what to do, but then meaningfully threw out a sentence, "I have always said that American wine is better than French wine!"

　　The New York Times said that shortly afterwards, Trump made another speech at the White House that day, further expounding the threat to France, saying that the French tax was "wrong" and his government was studying a possible wine tax. Trump told reporters, "Although I don’t drink, I always prefer American wine to French wine."

　　The New York Times said that this week, French President Macron signed a bill to impose a new digital tax on technology giants, and global Internet giants such as Facebook, Google and Amazon became potential targets. The tax rate is as high as 3%. The US Consumer News and Business Channel (CNBC) said that the Trump administration subsequently launched the 301 investigation under the Trade Act of 1974.

　　CNBC said that if after the investigation, the United States determines that this new tax is discriminatory or unreasonably targeted at American companies, Trump may respond with tariffs. Trade experts believe that Trump’s most likely response is to the French iconic product — — There is a 100% (import) tariff on wine.

　　"The Trump administration has always stated that it will not stand by and tolerate discrimination against American companies." This is what White House spokesman Judd Deere said in a statement on the 26th local time. The statement criticized France’s tax policy, but did not give any new details about what retaliatory measures the United States might take. Deere said that the government is "closely watching all other policy tools" except the investigation, so as to decide how to respond to France.

　　In the face of the tough stance of the United States, according to Agence France-Presse reported on 26th, French Economy Minister lemerre once said that Paris was not scared. "A universal tax on digital activities is a challenge for all of us. We hope to reach an agreement within the G7 and the OECD. At the same time, France will implement its own national decisions. "

　　CCTV News:On June 24th, the Dialogue on Investing in China CCTV Financial CBD Multinational Corporations, jointly sponsored by China Central Radio and Television General Station and China Council for the Promotion of International Trade, was launched in Beijing. At the event site, heads of relevant state ministries and commissions, executives of 49 multinational companies, representatives of more than 10 international organizations, mayors of hot investment cities and authoritative experts in the industry gathered together to discuss new opportunities for investment in China.

　　On-site guests: The event shows the latest achievements of China’s comprehensive deepening reform. Walking with China is walking with opportunities.

　　At the event, the guests agreed that the new development of China has brought new impetus and new opportunities to the world.

　　Huang Hanquan, president of the Macroeconomic Research Institute of the National Development and Reform Commission, said that the Dialogue on Investing in China CCTV Financial CBD Multinational Corporations showed an important window for China to comprehensively deepen the latest achievements of reform, and also provided an important platform for domestic and foreign enterprises to understand policies and increase exchanges. Walking with China is walking with opportunities; Investing in China means investing in the future. China economy is the main "engine" and "stabilizer" of world economic growth. At the same time, China is now accelerating the cultivation and development of new quality productivity, which will provide foreign-funded enterprises with new technologies, new equipment, new services and other market demands.

　　On-site guests said that in recent years, many multinational companies have achieved success by "investing in China". Now, a large number of multinational companies are still optimistic about the long-term potential of the China market, and are willing to continue to invest in China, deeply cultivate China and develop together.

　　Tang Yadong, secretary general of the European Union Chamber of Commerce in China, said that he had heard many successful stories of European companies in China and listened to their optimistic prospects in the market. He thinks it is very important for enterprises to know China. European companies see opportunities in China and enjoy the dividends. China has been opening its market and will continue to open it, and they hope this situation will continue.

　　Shi Mingde, chairman of the Asia-Pacific Tourism Association, said that he was very confident that China would continue to develop and prosper in tourism and the overall economy. The whole world is going through challenging times, but looking ahead, he is very optimistic about the future of China.

　　Sing the chinese’s bright economy on foreign-funded enterprises optimistic about China plus China

　　Over the years, many foreign-funded enterprises have achieved success by "investing in China". At the event, when interviewed by reporters, many executives of foreign-funded enterprises were generally full of confidence in China’s economic prospects, hoping to seize the opportunity and actively invest in China to achieve mutual benefit and win-win results.

　　The reporter learned that multinational companies that came to the event site have invested in five continents and gathered advanced productivity in aerospace, biopharmaceuticals and other fields. Some of them have been deeply cultivated in China for more than a hundred years, constantly increasing capital and expanding production, forming the "China practice" of global development; Others rely on China manufacturing to speed up the upgrading of industrial chain and run out of the "China speed" of high-quality development.

　　Shi Nathan, global vice president of Cummins and chairman of Cummins China, said that the scale of China market is the largest in the world, not only for them, but also for the whole market. If you want to be a global player, you must participate.

　　The data shows that from January to May 2024, newly established foreign-funded enterprises nationwide increased by 17.4% year-on-year, and the actual use of foreign capital reached a historical high. Many heads of foreign companies said that China’s perfect infrastructure, complete industrial base, complete supply chain, convenient logistics and transportation, and huge consumer market are the continuous driving forces for them to invest in China and take root in China. They are concerned about China’s accelerating the development of new quality productive forces and further expanding the pace of high-level opening to the outside world. They are optimistic about the long-term potential of the China market and are willing to continue to invest in China and deeply cultivate China.

　　Xu Xinxiong, global CEO of Tencel Group in Thailand and vice president of Thailand Chamber of Commerce in China, said that China is developing very fast, not only with high speed, but also with high quality, and they see more opportunities here.

　　Mark Mann, president of Danish Gryffindor China, said that investing in China means investing in innovation and sustainable development. They will continue to invest and maintain a good positioning, so as to continue to promote the high-quality growth of business partners and society.

　　Interpreting policies, increasing trust and dispelling doubts, government departments and foreign-funded enterprises talk about development together

　　On the day of the event, the government-enterprise dialogue meeting of foreign-funded enterprises was held simultaneously. In view of the concerns in investment and operation in China, a number of relevant department heads interacted with foreign-funded enterprises on the spot.

　　During the dialogue, heads of relevant departments such as the Ministry of Foreign Affairs, the Ministry of Finance, the Ministry of Agriculture and Rural Affairs, the General Administration of Customs, and the State Administration of Market Supervision interpreted policies on the spot, increased trust and dispelled doubts, and answered the questions and demands of more than 20 heads of multinational enterprises from 12 countries and regions with more accurate policy tools.

　　Foreign-funded enterprises are important participants, witnesses and contributors to the rapid economic development in China. Foreign-funded enterprises have been deeply involved in the China market, which has accelerated their own growth and gained returns.

　　Data show that in the past ten years, China has introduced about 140 billion US dollars of foreign capital every year on average. In the past five years, the rate of return of foreign direct investment in China is about 9%, which is at a high level in the world. On-site guests said that China is promoting Chinese modernization in an all-round way with high-quality development, accelerating the development of new-quality productive forces and steadily promoting institutional opening, which will provide a better business environment and stronger support for foreign-funded enterprises to invest in China with peace of mind.

　　Ren Hongbin, president of China Council for the Promotion of International Trade, said that the advantages of market, industry, talents and innovation will not change the fundamentals of China’s long-term economic development, which will bring new broad opportunities for the development of foreign-funded enterprises.

Original biological world biological world

Written by Cong Wang

Edit Wang Duoyu

Typesetting and writing in water

Epstein-Barr virus (EBV) is one of the most common viruses in the world. EBV is easily transmitted through body fluids (mainly saliva), such as kissing and sharing drinks or tableware. According to statistics, 90%-95% people around the world have been infected, usually in childhood.

EBV infection can cause infectious mononucleosis or similar diseases, but it usually has no symptoms. Most EBV infection symptoms are mild and will disappear, but these viruses will persist and lurk in the body, and will be reactivated. In recent years, some studies have shown that long-term latent EBV virus is related to some chronic inflammation and various cancers, and some studies have found that EBV may be the pathogenic factor of multiple sclerosis (MS).

On April 12th, 2023, the team of Professor Don Cleveland from the University of California, San Diego published a research paper entitled Chromosomal Fragile Site Breakage by EBV-Encoded EBNA 1 at clustered repeats in Nature.

This study describes for the first time how Epstein-Barr virus (EBV) uses the fragile sites in the human genome to cause chromosome breakage, cause cancer, and reduce the human body’s ability to suppress cancer.

There are fragile sites in everyone’s genome, and these specific chromosome regions are more prone to mutation, breakage or deletion during DNA replication. These changes may be related to disorders and diseases, which may lead to genetic diseases and cancer.

Professor Don Cleveland

Professor Don Cleveland, the correspondent of the paper, said that this study revealed how EBV induced the breakage of human chromosome 11 and caused a series of genomic instability, which may activate the oncogene that causes leukemia and inactivate the main tumor suppressor gene. This also proves for the first time how to selectively induce the breakage of fragile DNA sites.

In this latest study, the research team focused on EBNA1 protein, a viral protein that persists in human cells infected with EBV. Previous studies have shown that EBNA1 will bind to a specific genome sequence at the beginning of EBV genome replication. This study found that EBNA1 also combined with a cluster of EBV-like sequences at a fragile site of human chromosome 11, where the increase of protein abundance would lead to chromosome breakage.

Previous studies have shown that EBNA1 can inhibit p53 gene, and p53, known as the "genome guardian", plays a key role in controlling cell division and cell death. Under normal circumstances, p53 can inhibit the occurrence and development of tumors, while mutant p53 is related to the growth of cancer cells.

The research team also examined the genome-wide sequencing data of 2,439 cancers of 38 cancer types from the genome-wide pan-cancer analysis project. They found that tumors with EBV infection showed higher levels of chromosome 11 abnormalities, especially head and neck cancer cases.

Julia Su Zhou Li

Julia Su Zhou Li, the first author of the paper and a postdoctoral fellow, said that for a virus that is ubiquitous and harmless to most people, it is still an ongoing effort to identify high-risk groups susceptible to latent infection-related diseases. This study shows that the susceptibility to EBNA1-induced chromosome 11 breakage depends on the control of the level of EBNA1 protein produced in latent infection and the genetic variation of the number of EBV-like sequences on chromosome 11 in each individual. Looking ahead, this discovery paves the way for screening the risk factors for the development of diseases related to EBV infection. In addition, blocking the combination of EBNA1 and EBV-like sequence on chromosome 11 can be used to prevent the development of EBV-related diseases.

Paper link:

https://www.nature.com/articles/s41586-023-05923-x

Read the original text

China network television has a huge mobile client product cluster, covering many intelligent operating systems such as iOS, Android and windows phone, and two types of terminals, namely smart phones and tablet computers. It has mobile application products such as CCTV mobile TV, CBOX, live broadcast of China, I love Africa and CCTV column with the same name. At present, the global users of mobile clients have exceeded 51 million.
　　Among them, "CCTV News", as the only video news client in China, integrates CCTV’s huge news dissemination capabilities to provide the most comprehensive, authoritative and objective news reports for mobile users; "CCTV Audio & Video (CBox)" is deeply integrated by CNTV, the flagship product of mobile terminal, and CBox client, which is the flagship product of PC, to create an industry carrier-level video application.
　

　　Yang Guangwang Harbin April 25 th news (Reporter Pang Wei)April 25th is the National Child Vaccination Day.,This year’s publicity theme is "vaccination, disease prevention and control, health protection, life protection". Vaccination is the most economical and effective measure to prevent and control infectious diseases.,To this end,Heilongjiang ProvinceProvincial CDCPublish 61 articlesCommon knowledge of vaccinationquestions and answers.

Data Map Source: vision china

　　1 Q: What is a vaccine?

　　A: It refers to the preventive biological products used for human immunization in order to prevent and control the occurrence and epidemic of diseases, including immunization planning vaccines and non-immunization planning vaccines.

　　Q: What is an EPI vaccine?

　　A: It refers to the vaccines that residents should be vaccinated according to government regulations, including those determined by the national immunization program, those added by the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government when implementing the national immunization program, and those used by the people’s governments at or above the county level or their health authorities for emergency vaccination or mass vaccination.

　　Q: What is a non-EPI vaccine?

　　A: It refers to other vaccines voluntarily vaccinated by residents.

　　Q: What is a vaccine marketing license holder?

　　A: It refers to an enterprise that has obtained the registration certificate of vaccine drugs and the drug production license according to law.

　　Q: What is immunization program?

　　A: Immunization planning refers to the plans, plans and strategies formulated by using effective vaccines to vaccinate susceptible people according to the national infectious disease prevention and control plan, and to vaccinate people in a planned way according to the vaccine varieties, immunization procedures or vaccination programs determined by the state or provinces, autonomous regions and municipalities directly under the Central Government, so as to prevent and control the occurrence and prevalence of specific infectious diseases, and to improve people’s health level and health civilization level through the implementation of national immunization planning.

　　Q: What kind of immunization planning system does the country implement?

　　A: Residents living in China have the right to be vaccinated with EPI according to law and fulfill their obligations to be vaccinated with EPI. The government provides free immunization program vaccines to residents. The people’s governments at or above the county level and their relevant departments shall ensure that school-age children are vaccinated with immunization programs. The guardian shall ensure that school-age children are vaccinated with EPI vaccine on time according to law.

　　7 Q: What are the immunization program vaccines for school-age children in our province?

　　A: At present, the immunization programs for school-age children in our province include hepatitis B vaccine, BCG vaccine, inactivated polio vaccine, live attenuated polio vaccine, DTP vaccine, measles vaccine, live attenuated hepatitis A vaccine, live attenuated Japanese encephalitis vaccine, group A meningococcal polysaccharide vaccine and group A+C meningococcal polysaccharide vaccine.

　　Q: What is routine vaccination?

　　Answer: It refers to the vaccination service provided by the vaccination unit for the vaccinated object within a relatively fixed vaccination service cycle time in accordance with the national immunization program, vaccine use guidelines and vaccine use instructions.

　　Q: What is mass vaccination?

　　A: It refers to the organized and centralized vaccination activities for a specific group of people who may be threatened by an infectious disease within a specific scope and time. Supplementary immunization (formerly called "booster immunization") is a commonly used form of mass vaccination.

　　Q: What is emergency vaccination?

　　Answer: When the epidemic situation of infectious diseases begins or has an epidemic trend, vaccination activities are carried out for the target population in order to control the spread of infectious diseases.

　　Q: Why can vaccination prevent diseases?

　　A: Scientific research shows that when bacteria or viruses invade the human body, the body will produce a substance that resists the bacteria or viruses. This substance is called antibody. Different bacteria or viruses will produce different antibodies, which are called specific antibodies. After recovery, this specific antibody still remains in the body. If the corresponding bacteria or viruses invade the body again, this specific antibody can protect the body from these bacteria or viruses. Vaccination is to artificially inoculate a small amount of bacteria or viruses and their metabolites after being attenuated or inactivated, so that the body can produce specific antibodies or cellular immune responses, thus producing resistance against this pathogen.

　　Q: Why do you have to take vaccination according to the immunization program?

　　A: Different vaccines have different immunization procedures, which are based on clinical trials and years of scientific practice. Such as hepatitis B vaccine, pertussis-diphtheria-tetanus combined vaccine, polio vaccine, etc., at least three doses of vaccination are needed to make children have sufficient immunity. As children grow up, the immunity acquired by vaccination in the body will gradually decline. Therefore, some vaccines need to be strengthened.

　　Q: Can different vaccines be vaccinated at the same time?

　　A: Two or more injectable vaccines should be inoculated in different parts. It is forbidden to mix two or more vaccines and inhale them into the same syringe for inoculation. At present, all the vaccines in the national immunization program can be vaccinated at the same time according to the immunization procedure or the principle of replanting. Immunization planning vaccine and non-immunization planning vaccine can be vaccinated at the same time. If you choose not to vaccinate at the same time, priority should be given to ensuring immunization planning vaccine vaccination.

　　Q: How long does it take for different vaccines not to be vaccinated at the same time?

　　A: If two or more live attenuated vaccines for injection are not vaccinated at the same time, they should be vaccinated at an interval of ≥28 days. Inactivated vaccine and oral attenuated live vaccine, if they are not inoculated at the same time with other kinds of vaccines (including attenuated and inactivated), there is no restriction on the inoculation interval.

　　Q: How do migrant children get vaccinated?

　　A: In China, the vaccination of floating children is managed locally (that is, where they live), and floating children enjoy the same vaccination services as local children. If children under 6 years old move to other cities (regions) and counties (districts), they can directly carry the vaccination certificate issued by the health department of their original place of residence to the vaccination unit where they live now. If the vaccination certificate has not been handled before or is lost, the vaccination certificate can be reissued at the vaccination unit in the current residence.

　　Q: Which is better, imported vaccine or domestic vaccine?

　　A: Both domestic and imported vaccines have strict quality control systems to ensure the safety and effectiveness of vaccines. There is no obvious difference in performance between domestic vaccines and imported vaccines. No matter domestic or imported vaccines, all vaccines will have a certain level of adverse reactions, and there is no obvious difference in the level of adverse reactions between imported vaccines and domestic vaccines. Compared with domestic vaccines, imported vaccines have higher investment in R&D, and there is a certain gap between the prices of imported vaccines and domestic vaccines due to factors such as tariffs, freight and marketing costs. The choice of domestic vaccine or imported vaccine depends on the importance that individuals attach to the performance and price of the vaccine. If economic conditions permit, you can choose to vaccinate imported vaccines at your own expense, but if you consider the cost performance, it is also good to choose domestic vaccines. Don’t fall into the misunderstanding that the higher the price, the better.

　　Q: Why should BCG be vaccinated at birth?

　　Answer: After inoculation with BCG, the body can have specific immunity to Mycobacterium tuberculosis, which can prevent the reproduction and spread of Mycobacterium tuberculosis in the human body, so it has a good effect on preventing tuberculous meningitis and miliary tuberculosis. The World Health Organization suggests that newborns should be vaccinated with BCG as soon as possible in areas with high and moderate tuberculosis prevalence. China’s immunization program is to vaccinate newborns with one dose of BCG at birth.

　　Q: Why should newborns be vaccinated with hepatitis B vaccine within 24 hours after birth?

　　A: Most carriers of hepatitis B virus surface antigen in China come from vertical transmission from mother to child and early childhood infection. Because newborns have no immunity to hepatitis B virus and their immune function is not perfect, once they are infected with hepatitis B virus, they will easily become carriers of hepatitis B virus surface antigen. After infants less than one year old are infected with hepatitis B virus, more than 90% of them will become chronic hepatitis B virus surface antigen carriers. Thus, it is particularly important for newborns to prevent hepatitis B. All newborns should be vaccinated with the first dose of hepatitis B vaccine as soon as possible within 24 hours after birth, and complete the whole course of three doses of hepatitis B vaccine according to the immunization program of 0, 1 and 6 months old.

　　Q: Is it necessary to strengthen immunization after the whole vaccination of hepatitis B vaccine is completed?

　　A: At present, neither the World Health Organization nor China advocates the complete vaccination of hepatitis B vaccine and the booster immunization after successful immunization. This is because: after the successful initial immunization of hepatitis B vaccine, the immune persistence is good. According to domestic observation, the protection rate is still as high as 88.6% 15 years after vaccination. After natural exposure to hepatitis B virus (HBV), the memory B lymphocytes of successful immunization recipients inoculated with hepatitis B vaccine can rapidly proliferate, differentiate and produce specific antibodies after being attacked by HBV. It has been proved that humoral immune memory reaction still exists even among immunocompetents with low antibody or no antibody after 5 years. There is cellular immunity, and it has been observed that there is also specific cellular immune memory in addition to humoral immune memory response after vaccination with hepatitis B vaccine. Under the protection of hepatitis B vaccine, children can safely pass through the high-risk period of HBV infection (1 ~ 3 years old) without strengthening immunization, and with the function of immune barrier, the chances of infection of immunized children are greatly reduced. However, high-risk groups (such as hemodialysis patients, medical staff, etc.) should be tested for antibodies every 6 ~ 12 months, and when anti-HBS is less than 10 miu/ml, intensive vaccination can be carried out.

　　Q: How long will it take to have antibodies after hepatitis B vaccination? How long can it be protected?

　　A: Vaccination with hepatitis B vaccine is the most effective measure to prevent HBV infection. The effective component of hepatitis B vaccine is HBsAg, which induces human body to produce anti -HBs (hepatitis B surface antibody) and plays a role. After the first vaccination, most anti -HBs were still negative or below the lower limit of detection value; Anti -HBs turned positive about 1 week after the second injection, that is, it was immune to HBV 35-40 days after the start of inoculation; Inoculation with the third dose can significantly increase the level of anti -HBs and prolong the protection period. The positive conversion rate of anti -HBs is as high as 95%-100% after the whole vaccination of newborns, and the protection period can reach more than 22 years. After the human body actively produces anti -HBs, it has immune memory. Even if the anti -HBs turns negative and is exposed to HBV again, the body can produce anti -HBs in a short time. Therefore, it is not necessary for non-high-risk people to strengthen hepatitis B vaccination.

　　Q: What should adults do if they don’t produce antibodies after hepatitis B vaccination?

　　Answer: For those who fail to respond after three doses of hepatitis B vaccine, they can be vaccinated with one dose of 60μg or three doses of 20μg hepatitis B vaccine, and their serum anti -HBs will be detected 1-2 months after the second dose of hepatitis B vaccine. If there is still no response, they can be vaccinated with one dose of 60μg recombinant yeast hepatitis B vaccine.

　　Q: Can newborns of pregnant women infected with hepatitis B virus (HBV) breastfeed?

　　A: Although HBsAg and HBV DNA can be detected in the milk of pregnant women infected with hepatitis B virus, and some scholars believe that chapped nipples, excessive sucking of infants and even biting of nipples may transmit the virus to infants, these are theoretical analysis and lack of evidence-based medical evidence. Even without immunization, the infection rate of breast-fed and artificially fed newborns is almost the same. More evidence proves that even if pregnant women are HBeAg positive, breastfeeding does not increase the risk of infection. Therefore, after formal prevention, whether pregnant women are HBsAg positive or negative, their newborns can breastfeed, and there is no need to test whether there is HBV DNA in the milk.

　　Q: What should medical staff and others who accidentally expose hepatitis B virus do?

　　Answer: (1) Squeeze gently around the wound to discharge the blood in the wound, then rinse the wound with 0.9%NaCl solution, and then treat it with disinfectant. (2) HBV DNA and HBsAg should be detected immediately and rechecked after 3-6 months. (3) Those who have been vaccinated with hepatitis B vaccine and are known to be positive for anti -HBs (anti -HBs≥10mIU/ml) may not be treated. If you have not been vaccinated with hepatitis B vaccine, or if you have been vaccinated with hepatitis B vaccine, but the anti -HBs is less than 10 miu/ml or the anti-HBS is unknown, you should immediately inject 200-400 IU of HBIG, and at the same time, inoculate one dose of hepatitis B vaccine (20μg) in different parts, and then inoculate the second and third doses of hepatitis B vaccine (20μg) one month and six months later, respectively.

　　Q: Why should I stay on observation for at least 30 minutes after vaccination?

　　A: After vaccination, due to individual reasons, very few people may have allergic reactions. Monitoring data show that anaphylactic shock mostly occurs within 30 minutes after inoculation. After anaphylactic shock, if it is not under the supervision of medical staff, it is easy to be life-threatening. Therefore, doctors and first-aid drugs must be equipped at the inoculation site, mainly to prevent accidents. If the guardian suspects that his child has an adverse reaction to vaccination, he should consult or report to the vaccinator or the Center for Disease Control and Prevention in time.

　　Q: What is a suspected adverse reaction to vaccination?

　　A: It refers to the reaction or event that is suspected to be related to vaccination after vaccination.

　　Q: What are the classifications of suspected adverse reactions to vaccination?

　　A: It includes adverse reactions (general reactions and abnormal reactions), vaccine quality accidents, vaccination accidents, coupling diseases and psychogenic reactions.

　　Q: What are the conditions that do not belong to the abnormal reaction of vaccination?

　　A: The abnormal reaction of vaccination refers to the adverse drug reaction caused by the qualified vaccine in the process of implementing the standardized vaccination or after implementing the standardized vaccination, and the relevant parties have no fault.

　　The following situations do not belong to the abnormal reaction of vaccination:

　　(a) the general reaction after vaccination caused by the characteristics of the vaccine itself;

　　(2) Damage caused to the recipients due to vaccine quality problems;

　　(three) the damage caused to the recipients by the vaccination unit’s violation of the vaccination work norms, immunization procedures, guiding principles for vaccine use, and vaccination programs;

　　(four) the recipient is in the incubation period or precursor period of a disease at the time of inoculation, and the disease is coupled after inoculation;

　　(5) The recipient has vaccination contraindications specified in the vaccine instructions, and the recipient or his guardian failed to truthfully provide the health status and vaccination contraindications of the recipient before vaccination, and the original disease of the recipient has an acute recurrence or aggravation after vaccination;

　　(6) Psychogenic reactions of individuals or groups due to psychological factors.

　　Q: Why do some recipients have redness and inflammation in the injection area after vaccination?

　　A: Red swelling is a manifestation of inflammation and a common phenomenon in vaccination. It is the body’s responsive response to various damaging stimuli. It is characterized by local tissue deterioration, exudation and proliferation. When vaccinating, injection is often used, which itself can stimulate the human body to cause minor trauma and cause inflammation; At the same time, the vaccine itself is a foreign body and has certain toxicity. The pH, osmotic pressure and preservatives contained in the vaccine can cause inflammatory reactions to varying degrees. In addition, the inoculation of live vaccine is essentially a mild artificial infection, which can not only cause a mild infection process similar to the virulence of the microorganism, but also be accompanied by inflammatory reaction.

　　From the immunological point of view, inflammatory reaction is caused by the interaction between antigen and antibody or sensitized lymphocytes, which leads to the release of various inflammatory mediators by cells or the activation of inflammatory mediators in plasma or tissue fluid. Although the inflammation caused by vaccination may cause damage to the recipients, it is also conducive to the exudation of complement and antibody in the blood and strengthen the defense function.

　　Q: How to deal with the general reaction after vaccination?

　　A: After vaccination, you should stay in the vaccination unit for at least 30 minutes. Some children will have some reactions after vaccination, such as low fever, local redness and swelling, and may be accompanied by general discomfort, such as burnout, loss of appetite and fatigue. The above symptoms usually last for 1 ~ 2 days and disappear without any treatment. Children who have the above reactions after vaccination should take a proper rest, drink plenty of boiled water and keep warm to prevent other diseases from secondary. If there is a serious reaction, you should seek medical advice in time.

　　Q: Can children with neonatal jaundice be vaccinated?

　　A: Jaundice is a common clinical symptom in neonatal period, which can be divided into two types: physiological jaundice and pathological jaundice.

　　Physiological jaundice refers to the newborn’s 2 ~ 3 days after birth, which first appears on the face and neck, and then spreads all over the skin of trunk and limbs, with slight yellow staining and yellow sclera, but the palms and soles are not yellow, and the blood bilirubin is less than 12 mg/L, which reaches its peak on the 4 ~ 6 days after birth. Full-term infants mostly subside within 7 ~ 10 days after birth, and premature infants can delay to the 3 ~ 4 weeks. Children with physiological jaundice, except jaundice, are in good health, without other clinical symptoms, have normal urine and stool color, do not need treatment, have a good prognosis, and can be vaccinated with various vaccines.

　　Pathological jaundice can be divided into infectious jaundice and non-infectious jaundice (hemolytic disease of newborn, biliary atresia, breast-feeding jaundice, genetic diseases and drug-induced jaundice). If neonatal jaundice occurs in one of the following situations, it should be considered whether it is pathological jaundice: jaundice occurs within 24 hours; The degree of jaundice is deep and progresses rapidly, exceeding 6 mg/d L； in one day; Blood bilirubin > 12 mg/l; Jaundice lasts more than 2 weeks or reappears after it subsides. Pathological jaundice is the manifestation of the disease, and it should be treated in time, and vaccination is not allowed.

　　Q: Can allergic constitution be vaccinated?

　　A: The so-called "allergic constitution" is not a contraindication for vaccination. Allergic reactions are mild and severe, and serious allergic reactions caused by vaccines are rare. Compared with the risk of illness without vaccination, the benefit of vaccination is greater. The so-called "allergic constitution" can be observed after vaccination. If there are allergic manifestations, they can be treated in time, which generally will not affect health (nor affect the vaccination effect). If you are seriously allergic to the known vaccine ingredients or have laryngeal edema, anaphylactic shock and other serious systemic allergic reactions due to vaccination in the past, it is forbidden to continue to vaccinate the same vaccine.

　　Q: What common diseases are not taboo for vaccination at present?

　　A: Physiological and breast-feeding jaundice, history of simple febrile convulsion, stable epilepsy control, congenital inherited metabolic diseases (congenital hypothyroidism, phenylketonuria, trisomy 21 syndrome, etc.), stable brain diseases, congenital heart disease, congenital infection (syphilis, cytomegalovirus and rubella virus), etc.

　　Q: Is it necessary to vaccinate Covid-19 vaccine?

　　A: It is necessary. On the one hand, most people in our country have no immunity against Covid-19, and they are susceptible to Covid-19. After the onset of infection, some people will develop into critical illness and even cause death. After vaccination, on the one hand, most people can gain immunity, thus effectively reducing the risk of illness, severe illness and death; On the other hand, through the orderly vaccination of Covid-19 vaccine, we can gradually establish an immune barrier among the population, stop the epidemic of COVID-19, and restore the normal operation of China’s social economy and residents’ life as soon as possible.

　　Q: How does Covid-19 vaccine work in human body?

　　A: After vaccination, the human body will produce protective antibodies, and some vaccines will also make the human body have cellular immunity and form corresponding immune memory. In this way, the human body has immunity against diseases. Once Covid-19 invades the human body, antibodies produced by vaccines and cytokines released by cellular immunity can identify, neutralize or kill the virus, and immune memory can quickly mobilize the immune system to play a role, so that the virus cannot continue to proliferate in the body, thus achieving the purpose of preventing diseases.

　　Q: At present, how many kinds of Covid-19 vaccines have been approved for conditional marketing or emergency use in China?

　　A: Covid-19 vaccines from five manufacturers in China have been approved for conditional marketing or emergency use. Among them, there are 3 inactivated vaccines and 1 adenovirus vector vaccine approved for marketing conditionally; In addition, one recombinant Covid-19 vaccine (CHO cells) was approved for emergency use.

　　Q: Who are the approved vaccine manufacturers in Covid-19?

　　A: The three Covid-19 inactivated vaccine products that have been conditionally approved for marketing are produced by Sinopharm China Bio-Beijing Institute of Biological Products (Beijing Institute), Wuhan Institute of Biological Products (Wuhan Institute) and Beijing Kexing Zhongwei Biotechnology Co., Ltd. (Kexing Zhongwei).

　　The adenovirus vector vaccine approved for marketing conditionally is produced by Kangxinuo Bio-stock Company (Kangxinuo).

　　The recombinant subunit vaccine approved for emergency use is produced by Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. (Zhifeilong Kema).

　　Q: At this stage, who is the target of Covid-19 vaccine?

　　A: The vaccination target of Covid-19 vaccine in China is people aged 18 and above.

　　Q: At present, how many doses of Covid-19 vaccine are required to be used in China? How long is the interval?

　　A: At present, Covid-19 inactivated vaccine needs to be inoculated with two doses; The interval between the first dose and the second dose should be 3 weeks or more, and the second dose should be completed as soon as possible within 8 weeks after the first dose.

　　Adenovirus vector vaccine needs 1 dose.

　　The recombinant subunit vaccine needs 3 doses; The interval between the first dose and the second dose, and the interval between the second dose and the third dose are suggested to be 4 weeks or more. The second dose should be completed within 8 weeks after the first dose and the third dose should be completed within 6 months after the first dose.

　　Q: Where can I get the Covid-19 vaccine?

　　A: Vaccination in Covid-19 is carried out in vaccination units approved by local health administrative departments. Usually, the inoculation unit is located in the health service center, township health center or general hospital in the jurisdiction. If vaccination involves some departments or enterprises with relatively concentrated key targets, some temporary vaccination units will be set up locally according to the situation.

　　The health administrative department or disease prevention and control institution in the jurisdiction will also announce the vaccination units that can carry out Covid-19 vaccination as required, including the location and service hours. Please pay attention to the relevant information release platform.

　　Q: What are the contraindications for COVID-19 vaccination?

　　A: The taboo of vaccination refers to the situation that vaccination should not be given. According to the Technical Guide for Vaccination in Covid-19 (First Edition), the common taboos for vaccination include: 1. Those who are allergic to the active ingredients, any inactive ingredients and substances used in the production process, or those who have been allergic to similar vaccines before; 2. Those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioneurotic edema, dyspnea, etc.); 3. People with uncontrolled epilepsy and other serious nervous system diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.); 4. Those who are suffering from fever, or acute diseases, or acute attacks of chronic diseases, or patients with uncontrolled serious chronic diseases; 5. Pregnant women. Some taboos, such as fever, are temporary. When the situation that caused the taboo no longer exists, you can vaccinate later.

　　Q: How to find and grasp the taboo of vaccination?

　　A: During the operation, if the first dose of vaccine causes severe allergic reaction, and it cannot be ruled out that it is caused by the vaccine, it is not recommended to vaccinate the second dose. To understand the ingredients of the vaccine, people who have been allergic to the ingredients of the vaccine in the past cannot be vaccinated.

　　At the time of vaccination, the recipient should truthfully report the physical health status, disease history and allergy history to the vaccination doctor; The vaccination doctor will ask about the health status and past allergy history of the recipient.

　　Q: Can Covid-19 vaccines from different manufacturers replace vaccination?

　　A: According to the Technical Guide for Vaccination in Covid-19 (First Edition), it is suggested to complete the whole vaccination with inactivated Covid-19 vaccine from the same company at this stage. In case of special circumstances, such as the vaccine can’t continue to be supplied, the recipients are inoculated in different places, and the whole process of vaccination can’t be completed with the inactivated vaccine of Covid-19 from the same enterprise, the inactivated vaccine produced by other enterprises can be used to complete the vaccination.

　　Q: Where and how to vaccinate Covid-19 vaccine?

　　A: At present, the five Covid-19 vaccines have been approved for inoculation in deltoid muscle of upper arm, and the inoculation route is intramuscular injection.

　　Q: What should we pay attention to in the process of vaccination in Covid-19?

　　A: During the vaccination process, the recipients should pay attention to and cooperate with the following matters:

　　Before vaccination, you should know about COVID-19’s disease, Covid-19’s vaccine and vaccination process in advance.

　　When vaccinating, you need to bring relevant certificates (ID card, passport, etc.), do personal protection according to local prevention and control requirements, cooperate with the on-site vaccination staff to ask, and truthfully provide information such as my health status and vaccination contraindications.

　　After inoculation, you need to stay for 30 minutes; Keep the skin of the inoculated area clean and avoid scratching the inoculated area with your hands; If there is any suspected adverse reaction, report it to the inoculation unit and seek medical treatment in time if necessary.

　　Q: Why do you have to stay on observation for half an hour after vaccination?

　　A: After vaccination, very few people may have acute allergic reactions and syncope. Acute allergic reactions that seriously endanger life safety often occur within 30 minutes after vaccination. In case of acute allergic reaction, you can take timely treatment measures at the scene. Syncope also occurs mostly within half an hour after inoculation. If you leave the observation site immediately after inoculation, you may cause accidental injury to the recipient due to syncope. Therefore, the recipients need to stay in the designated area of the vaccination unit for half an hour after vaccination.

　　Q: Why do you need a certain interval between doses of inactivated vaccine in Covid-19?

　　A: Usually, inactivated vaccines need to be vaccinated several times to achieve better immune effect. According to the clinical trial data, the first dose of inactivated vaccine in COVID-19 can stimulate the body to produce partial immune response, and the second dose can produce better immune effect. The interval between doses generally needs to be determined according to the results of clinical trials. If two doses of inoculation are not completed within the time required by the program interval, replanting should be done as soon as possible.

　　Q: How to replant those who have not completed the whole immunization program? Do you need to start over?

　　Answer: For vaccines with two or three doses of immunization, those who have not been vaccinated in the whole process are advised to replant the unfinished doses as soon as possible, and there is no need to restart vaccination according to the immunization program.

　　Q: Do people whose interval between two doses of inactivated Covid-19 vaccine is less than 3 weeks need replanting?

　　Answer: For those who have completed two doses of inactivated vaccine in Covid-19 within 14 days, one dose of inactivated vaccine should be replanted as soon as possible three weeks after the second dose. For those who complete 2 doses of inactivated Covid-19 vaccine in 14-21 days, there is no need to replant.

　　Q: Is it necessary to strengthen immunization after the whole vaccination of inactivated vaccine in Covid-19 at this stage?

　　A: Strengthening immunization is not recommended at this stage.

　　Q: It was suggested that HPV vaccine and Covid-19 vaccine should not be vaccinated at the same time. How long should the interval be?

　　A: Covid-19 vaccine is a new vaccine. In order to identify or distinguish possible suspected adverse reactions of vaccine, it is not recommended to vaccinate Covid-19 vaccine together with other vaccines (including HPV vaccine) at present. However, it doesn’t mean that you can’t vaccinate other vaccines after Covid-19 vaccination, but it is suggested that Covid-19 vaccine and other vaccines should be vaccinated more than two weeks apart. It must be noted that when rabies vaccine, tetanus vaccine and immunoglobulin need to be vaccinated urgently due to animal injury, trauma and other reasons, the vaccination interval with Covid-19 vaccine may not be considered.

　　Q: Can women of childbearing age and lactation be vaccinated with Covid-19 vaccine?

　　A: If you are pregnant after vaccination or have been vaccinated in the case of unknown pregnancy, based on the understanding of vaccine safety, it is not recommended to take special medical measures (such as termination of pregnancy) just because you have been vaccinated with Covid-19 vaccine. It is recommended to do a good job in pregnancy examination and follow-up. For women who have a pregnancy plan, it is not necessary to delay the pregnancy plan just because of Covid-19 vaccination.

　　Although there is no clinical research data on the effect of Covid-19 vaccine on lactating infants, based on the understanding of vaccine safety, it is suggested to vaccinate lactating women (such as medical staff) who are at high risk of Covid-19 infection. Considering the importance of breast-feeding for infants’ nutrition and health, and referring to the international practice, it is suggested that breast-feeding should be continued after breast-feeding women are vaccinated with Covid-19 vaccine.

　　Q: Can people aged 60 and above be vaccinated with Covid-19 vaccine?

　　A: People aged 60 and above are at high risk of severe illness and death after being infected with Covid-19. At present, the number of four phase III clinical trials of Covid-19 vaccine approved for marketing is limited, and the phase III trial of recombinant subunit vaccine is still in progress, and there is no data on the protective efficacy of the vaccine for this population. However, the data of the above-mentioned phase I/II clinical study of the vaccine show that the vaccination safety of this population is good. Compared with the population aged 18-59, the titer of neutralizing antibody after vaccination is slightly lower, but the positive conversion rate of neutralizing antibody is similar, suggesting that the vaccine will also have a certain protective effect on people over 60 years old, so vaccination is recommended.

　　Q: Can people with chronic diseases be vaccinated with Covid-19 vaccine?

　　A: People with chronic diseases are people with high risk of severe illness and death after being infected with Covid-19. People with chronic diseases with stable health and good drug control should not be considered as the taboo population for vaccination in Covid-19, so vaccination is recommended.

　　Q: Can people with impaired immune function be vaccinated with Covid-19 vaccine?

　　A: People with impaired immune function are people with high risk of severe illness and death after Covid-19 infection. At present, there is no data on the safety and effectiveness of Covid-19 vaccine for this population (such as malignant tumor, nephrotic syndrome, AIDS patients) and human immunodeficiency virus (HIV) infected people. The immune response and protective effect of this group of people may be reduced after vaccination. For inactivated vaccine and recombinant subunit vaccine, according to the safety characteristics of the same type of vaccine in the past, vaccination is recommended; For adenovirus vector vaccine, although the vector virus used is replication-deficient, there is no safety data of the same type of vaccine in the past. It is recommended to vaccinate after being fully informed that the benefits outweigh the risks.

　　Q: Do I need to get Covid-19 vaccine if I have been infected with Covid-19?

　　A: The existing research data show that it is rare to get reinfected in Covid-19 within 6 months after infection. Previous COVID-19 virus-infected people (patients or asymptomatic infected people) can receive one dose after 6 months on the basis of full notification.

　　Q: How long will it take to produce antibodies against Covid-19 after Covid-19 inactivated vaccine is inoculated?

　　A: According to the previous clinical trial of inactivated vaccine in Covid-19, the vaccinated population can have a good immune effect about two weeks after the second dose of inactivated vaccine is inoculated.

　　Q: Is it necessary to test antibodies before and after vaccination?

　　A: There is no need to carry out Covid-19 nucleic acid and antibody testing before vaccination; Routine antibody detection after vaccination is not recommended as the basis for successful immunization.

　　Q: Do I still need to do nucleic acid testing after Covid-19 vaccination? Can vaccination certificate replace nucleic acid test report?

　　Answer: After vaccination with Covid-19 vaccine, a very small number of the recipients still have positive nucleic acid test or illness due to protection failure: 1. After the whole vaccination, some people failed to get effective protection due to immune failure. After exposure to Covid-19, this group of people may be infected with Covid-19 and have positive nucleic acid test or illness. 2. It takes some time to produce protective effect after vaccination. If you are infected with Covid-19 during this period, you may detect nucleic acid positive or get sick. 3. Patients who are in the incubation period of the disease or asymptomatic infected people may still detect nucleic acid positive or get sick because they have been infected even after vaccination.

　　These people may become infected persons. When the prevention and control of epidemic situation in COVID-19 needs to be screened for nucleic acid, Covid-19 vaccination certificate cannot replace the nucleic acid test report, and it is necessary to cooperate with relevant departments to carry out nucleic acid test.

　　Q: After the mutation in Covid-19, is Covid-19 vaccine still effective?

　　A: According to the global monitoring of Covid-19 mutation, there is no evidence that virus mutation will invalidate the existing Covid-19 vaccine. Virus is one of the simplest organisms, and its proliferation depends on living cells. In the process of proliferation, the virus will mutate. The World Health Organization, research institutions in various countries, vaccine manufacturers, etc. are paying close attention to the mutation situation in Covid-19, and are also carrying out related research, which will provide early warning and scientific analysis basis for the follow-up vaccine development and application.

　　Q: What are the common adverse reactions of vaccination in Covid-19?

　　A: According to the results of the previous clinical trial of Covid-19 vaccine and the information collected during emergency use, the common adverse reactions of Covid-19 vaccine in China are basically similar to those of other vaccines that have been widely used. Common adverse reactions are mainly manifested as redness, induration and pain at the inoculation site, as well as clinical manifestations such as fever, fatigue, nausea, headache and muscle soreness. Relevant departments will continue to strengthen the real-time monitoring and evaluation of adverse reactions.

　　Q: Will our prevention and control measures be adjusted after vaccination in COVID-19?

　　A: For individuals, the protective effect of vaccination is not 100%, and it takes some time to produce protective antibodies. For the population, Covid-19 is still easy to spread without forming an immune barrier. Therefore, in order to prevent the COVID-19 epidemic from rebounding, some prevention and control measures should still be adhered to at this stage, including wearing masks, keeping social distance, washing hands frequently, ventilation and other protective measures. The prevention and control measures for COVID-19 epidemic will be adjusted in time with the improvement of vaccine coverage rate in COVID-19 and the change of epidemic situation at home and abroad.

　 　 　 　Directed by Yachun Dong, starring Tang Guoqiang and Ding Yongdai, and starring Sun Weimin, WangZhifei, Liu Zhibing, Yao Gang, Wang Ting, Wang Tonghui, Liu Tao and Chen Kaixin, the film "Crossing the Yalu River", which shows the great war to resist US aggression and aid Korea, has recently been shown in national cinemas. Many viewers have entered the cinema, recalling the epic history and remembering the revolutionary martyrs.

　 　 　 　The film Crossing the Yalu River is a "panoramic, epic" major revolutionary historical work that shows the War to Resist US Aggression and Aid Korea. The film material is basically taken from a TV series of the same name "Crossing the Yalu River" which premiered in the central government at the end of last year. Forty episodes of TV series were condensed into two and a half hours of movies, which were told for the first time from the perspective of Peng Dehuai, commander and political commissar of Chinese people’s Volunteer Army. From the strategic thinking of the central leadership, the battlefield strategy of the volunteers generals, the bloody battles of the frontline volunteers and other dimensions, the epic battles in the East-West Line and five battles were reproduced, and the magnificent history was fully restored.

　 　 　 　?

　 　 　 　"When the volunteer soldiers fought in the front, the dangers we encountered were unimaginable. I am very grateful to have such a work to restore this history, so that we can feel the ruthlessness of the war through movies, feel the selflessness and greatness of the revolutionary ancestors, and be immortal. China Volunteers, the most lovely person!" Walking out of the cinema, Ms. Li, an audience in Haikou, said emotionally.

　 　 　 　It is reported that since the film "Crossing the Yalu River" was released, many viewers have expressed "want to see it", and enterprises and institutions plan to organize employees to watch the movie in a centralized way. "At present, our studio has received booking orders from several units, which will be available tomorrow and the day after tomorrow." The person in charge of Xingyu IMAX Studios Haikou Wuyue Plaza Store said.

　 　 　 The film Crossing the Yalu River was produced by the Central Radio and Television General Station, produced by the TV Drama Documentary Center of the General Station, produced by the China TV Drama Production Center of the General Station, and jointly produced by Huaxia Film Distribution Co., Ltd.

China has 41,179 movie screens, ranking first in the world.

　　In 2016, the total box office of national movies was 45.712 billion, up 3.73% year-on-year. Compared with the growth rate of 48.7% last year, the good momentum has come to an abrupt end. In addition to the steady growth in the first quarter (Spring Festival file) last year, the box office was negative for five months in the next nine months.

　　Nearly 60% of the films made were not released.

　　In 2016, the number of cinema visitors in the city was 1.372 billion, an increase of 8.89% year-on-year. The growth rate of movie attendance is greater than that of box office, indicating that the average fare has decreased, and the national average fare is about 33.32 yuan.

　　In 2001, there were 84 films with box office exceeding 100 million yuan, including domestic movie 43 films. The box office of domestic films was 26.663 billion, accounting for 58.33% of the total box office, once again exceeding that of imported films. This year, many imported films are actually sponsored by domestic investors, such as Kung Fu Panda 3, Crouching Tiger, Hidden Dragon 2, or participated in the project, such as Warcraft, Bourne ultimatum 5, Star Trek 3, revenant, Hacksaw Ridge, Billy Lynn’s Long Halftime Walk and Nine Lives.

　　In the whole year, 772 feature films, 49 animated films, 67 science and education films, 32 documentary films and 24 special films were produced, totaling 944. Among them, less than 400 films have been shown in cinemas, accounting for 42%. In other words, nearly 60% of the films made have not been shown.

　　In 2016, there were 1,612 new cinemas and 9,552 new screens. At present, the total number of screens in China has reached 41,179 (more than 7,600 cinemas), surpassing the North American market (about 39,000) and becoming the country with the largest number of movie screens in the world. Last year, the number of screens in the world increased by 11,260, an increase of 8%, totaling 152,000. Among them, the number of screens in China increased by 8035, accounting for 71.36%. Judging from the changes in the past two years, the proportion of China’s screens in the world should be 21%-25%.

　　Hollywood blockbusters rely on China to attract gold.

　　In 2016, 724 movies were released in North America, with a box office of $11.25 billion, which was basically the same as last year. In fact, for many years, the mature North American market has maintained a stable state, and the number of people watching movies and the box office have not increased or decreased by more than 10%.

　　Therefore, overseas, especially China, has become a key market for major Hollywood film companies. Hollywood has been doing well, too. Many blockbusters have far more overseas box office than those in North America. For example, Captain America: Civil War, which has the highest box office in the world this year, has 64.6% overseas box office. For example, Kung Fu Panda 3 and Warcraft, the overseas box office accounts for 72.5% and 89.1% respectively. And a large part of these overseas box offices are sold in China. For example, the box office of Warcraft in China is as high as 1.472 billion RMB, which is equivalent to 212 million US dollars at the current exchange rate, accounting for 55% of the overseas box office of 386.3 million US dollars.

　　Because the China market is too big, the box office of a Mermaid in Stephen Chow is as high as 3.393 billion, ranking 12th in the global box office list in terms of US dollars. Compared with China, its North American box office is only $3.23 million, accounting for 0.6% of the global total box office. (According to Sohu)

　　Recently, respiratory diseases have been high.

　　"Syncytial virus" topped the hot search list.

　　Some netizens asked questions.

　　"What is this?"

　　Syncytial virus is not a new respiratory disease.

　　Syncytial virus is not a new respiratory disease, and there was an anti-seasonal epidemic this summer.

　　Tang Zhichao, deputy director of the Department of Disease Control, Shunyi Women and Children Hospital, Beijing Children’s Hospital, said that respiratory syncytial virus is the most important virus pathogen that causes acute lower respiratory infection in children under 5 years old worldwide. Respiratory syncytial virus (RSV) infection is the primary cause of hospitalization of infants with viral respiratory infection, which seriously harms children’s health, especially premature infants and infants with congenital heart disease or primary immunodeficiency.

　　Children and adults can be infected.

　　Source: Yangguang. com

　　Syncytial virus is an RNA virus, which is transmitted by droplets and close contact, or by contaminated hands and objects. Patients often have upper respiratory symptoms after infection.

　　The incubation period of syncytial virus is usually 2-8.
Days, detoxification can last for 1-3 weeks. Early infection is mostly confined to the upper respiratory tract, showing symptoms of upper respiratory tract such as nasal congestion, runny nose, cough and hoarseness.

　　The typical symptoms of children infected with syncytial virus are fever, cough, stuffy nose and runny nose.

　　The typical symptoms of adult infection are very similar to the common cold, such as low-grade fever, cough, stuffy nose and runny nose.

　　Most patients’ symptoms will disappear spontaneously within 1-2 weeks, and a small number can develop into lower respiratory tract infection (i.e. bronchiolitis or pneumonia), which is more common in young infants. Clinical symptoms include cough and wheezing.

　　Gao Weiwei, chief physician of neonatal respiratory department of Guangdong Maternal and Child Health Hospital, said that syncytial virus is about 2.5 times as contagious as influenza.

　　At present, there are no syncytial virus vaccines and special therapeutic drugs on the market in China. Syncytial virus can be repeatedly infected and easily spread at home. In the absence of vaccines and effective drugs, measures such as strengthening personal protection should be taken to prevent infection.

　　The doctor reminds: Don’t overdo it and don’t "mix and match".

　　Recently, Xiao Zhao, a 16-year-old high school student, was admitted to the emergency intensive care unit for taking four kinds of cold medicines. Xiao Zhao found that she had symptoms of a cold and a little fever, so she took ibuprofen and crack at the same time. After taking the medicine, he felt that his symptoms were not obviously relieved, so he added two other cold medicines, which is equivalent to taking four cold medicines together.

　　Source: CCTV News

　　Gan Yongxiong, Chief Physician of Emergency Intensive Care Unit of Fangqiao Campus of the First Affiliated Hospital of Ningbo University: After being sent to the hospital, after our doctor’s judgment, we finally made it clear that it was acute renal failure and rhabdomyolysis, which was the effect of the superposition of these cold medicines on the kidneys.

　　The doctor reminded not to take too much medicine and not to "mix and match". Patients should pay attention to the drug instructions when taking drugs by themselves, and should not increase or decrease the types and doses of drugs at will. Even if you only take one drug, you can’t increase or decrease the dose at will. If multiple drugs need to be taken at the same time, it is best to consult a doctor in advance and take them according to the doctor’s advice. If you accidentally take too much medicine and cause discomfort, you should seek medical advice in time, inform the doctor in detail about the recent medication, and actively cooperate with the treatment.

　　In view of the recent increase in the number of outpatient and emergency departments in some places and the increase in the number of children infected with respiratory diseases, the responsible comrades of the National Health and Wellness Commission answered questions of concern to some people, especially the families of children, in an interview on November 23.

　　Q:

　　Recently, many local children’s specialized hospitals are overcrowded. What measures has National Health Commission taken to relieve them?

　　A:

　　Recently, we have continued to pay attention to the diagnosis and treatment of children susceptible to infectious diseases during the high incidence period, and guided all localities to strengthen overall planning and implement a graded diagnosis and treatment system.

　　Q:

　　Some community hospitals have recently set up inspection services for children, but some parents are worried that the lack of diagnosis and treatment capacity in community hospitals will delay their children’s illness. What should I do?

　　A:

　　National Health Commission has asked all localities to give full play to the role of medical associations, strengthen technical guidance to primary medical and health institutions, and improve the diagnosis and treatment ability of common infections and the efficiency of severe identification and referral.

　　Q:

　　Which hospitals are qualified to accept children with respiratory tract infection?

　　A:

　　National Health Commission has instructed all localities to publicize the information of medical institutions that can provide pediatric diagnosis and treatment services in the region, so as to facilitate the nearest medical treatment.

　　Q:

　　What should children do after they have a fever and cough?

　　A:

　　Large hospitals are crowded with people, waiting for a long time, and the risk of cross-infection is high. It is suggested that children with mild symptoms should first go to primary medical and health institutions and pediatrics of general hospitals. After seeing a doctor in a children’s specialist hospital, they can also be referred to primary medical institutions for follow-up treatment or home treatment through medical associations.

　　Q:

　　What conditions must the child go to the hospital for medical treatment?

　　A:

　　According to experts’ advice, children should take their children to see a doctor in time if they have ultra-high fever or persistent fever for more than three days, frequent cough affects their normal life, poor mental state or even drowsiness, increased respiratory rate or dyspnea, frequent vomiting, rash, headache or convulsions.

　　From: Xinhua Viewpoint